年轻成人IDH野生型胶质母细胞瘤中EGFR拷贝数增益的不良预后影响
本研究回顾性分析2014-2018年本机构28例18-45岁新诊断IDH野生型胶质母细胞瘤患者,其中36%存在EGFR拷贝数增益,与更短的至肿瘤进展时间和总生存期相关,多变量模型显示总生存期风险比6.40。TCGA验证队列43例中趋势一致但未达统计学显著。
要点
- 年轻成人IDH野生型胶质母细胞瘤中EGFR拷贝数增益发生率36%。
- EGFR拷贝数增益与更短的总生存期独立相关(HR 6.40)。
- TCGA验证队列趋势一致但未达统计学显著。
核心结论
- EGFR拷贝数增益可能与年轻成人新诊断IDH野生型胶质母细胞瘤的不良结局相关。
研究设计与样本
- 回顾性队列研究,纳入本机构2014-2018年28例18-45岁新诊断IDH野生型胶质母细胞瘤且肿瘤接受二代测序的患者。
- 验证队列为TCGA中43例18-45岁IDH野生型胶质母细胞瘤患者。
主要发现
- EGFR拷贝数增益与更短的总生存期相关(中位16.3 vs. 23.5个月;p=0.047)。
- 多变量模型中EGFR拷贝数增益对总生存期的负面预后影响持续存在(HR 6.40,95%CI 1.3-31.0,p=0.02)。
- TCGA队列中EGFR拷贝数增益与更短的至肿瘤进展时间和更差的总生存期相关,但未达统计学显著(至肿瘤进展时间中位11.5 vs. 14.4个月,p=0.18;总生存期中位23.6 vs. 27.8个月,p=0.18)。
临床怎么用
- 在年轻成人IDH野生型胶质母细胞瘤中可考虑检测EGFR拷贝数增益以辅助预后分层。
- EGFR拷贝数增益提示该人群可能从靶向EGFR的治疗中获益,但需进一步研究验证。
局限性
- 本机构队列样本量小(28例),验证队列样本量也有限(43例)。
- 为回顾性研究,可能存在选择偏倚。
- TCGA验证队列中EGFR拷贝数增益的预后影响未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Young adults with isocitrate-dehydrogenase wild-type (IDH-WT) glioblastoma (GBM) represent a rare, understudied population compared to pediatric high-grade glioma, IDH-mutant GBM, or IDH-WT GBM in older patients. We aimed to explore the prognostic impact of epidermal growth factor receptor copy number gain (EGFR CN gain), one of the most common genetic alterations in IDH-WT glioma, in young adults with IDH-WT GBM. METHODS: We performed a retrospective cohort study of patients 18-45 years old with newly diagnosed, IDH-WT GBM whose tumors underwent next-generation sequencing at our institution between 2014 and 2018. The impact of EGFR CN gain on time to tumor progression (TTP) and overall survival (OS) was assessed. A validation cohort of patients 18-45 years old with IDH-WT GBM was analyzed from The Cancer Genome Atlas (TCGA). RESULTS: Ten of 28 patients (36%) from our institution had EGFR CN gain, which was associated with shorter TTP (median 6.5 vs. 11.9 months; p = 0.06) and OS (median 16.3 vs. 23.5 months; p = 0.047). The negative prognostic impact of EGFR CN gain on OS persisted in a multivariate model (HR 6.40, 95% CI 1.3-31.0, p = 0.02). In the TCGA cohort (N = 43), EGFR CN gain was associated with shorter TTP and worse OS, although these did not reach statistical significance (TTP, median 11.5 vs. 14.4 months, p = 0.18; OS, median 23.6 vs. 27.8 months; p = 0.18). CONCLUSIONS: EGFR CN gain may be associated with inferior outcomes in young adults with newly diagnosed, IDH-WT GBM, suggesting a potential role for targeting EGFR in this population.
引用
- Hoffman DI, Abdullah KG, McCoskey M, et al. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma. J Neurooncol. 2019. PMID: 31542863. doi:10.1007/s11060-019-03298-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。